fimasartan

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
051020112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Angiotensin receptor blockers (ARBs) have organ-protective effects in heart failure and may be also effective in doxorubicin… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
OBJECTIVES A newly developed angiotensin II receptor blocker, fimasartan, is effective in lowering blood pressure through its… (More)
Is this relevant?
2015
2015
BACKGROUND The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
BACKGROUND Angiotensin II receptor blockers (ARBs) play a key role in hypertension therapy. Recently, fimasartan, the ninth ARB… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
The authors studied the effects of ketoconazole and rifampicin on the pharmacokinetics of a single dose of fimasartan (BR-A-657… (More)
Is this relevant?
2012
2012
AIM Fimasartan is a selective angiotensin II receptor blocker. Hydrochlorothiazide (HCTZ), which is used to treat hypertension… (More)
Is this relevant?
2011
2011
AIM Fimasartan (BR-A-657) is a new angiotensin II receptor antagonist used as antihypertensive agent. The objective of this study… (More)
Is this relevant?
2011
2011
OBJECTIVES The aim of this study was to compare the pharmacokinetics (PK) and safety of fimasartan (BR-A-657), an angiotensin II… (More)
Is this relevant?
2011
2011
UNLABELLED Fimasartan (BR-A-657) is an angiotensin II receptor antagonist, recently approved as an antihypertensive agent… (More)
Is this relevant?
2011
2011
BACKGROUND AND OBJECTIVES Fimasartan (BR-A-657) is a novel, non-peptide angiotensin II receptor antagonist with a selective type… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?